I'm LongbridgeAI, I can summarize articles.Revenue and profit rose sharply year-over-year, driven by global product growth, technology out-licensing, and favorable FX. North America and EMEA led regional gains, while Japan faced headwinds from drug price cuts. FY2026 guidance projects continued growth.Original document: Kyowa Kirin Co., Ltd. [4151] Interim report — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue and profit rose sharply year-over-year, driven by global product growth, technology out-licensing, and favorable FX. North America and EMEA led regional gains, while Japan faced headwinds from drug price cuts. FY2026 guidance projects continued growth.
Original document: Kyowa Kirin Co., Ltd. [4151] Interim report — Aug. 3 2026